Leuprolide acetate market share?

I don’t have real-time market-share numbers here. Market share for leuprolide acetate products varies by region, year, and whether you’re looking at brand-only vs. including generics or by prescriptions vs. sales.

If you can share:
- region (US, global, or another country)
- year or range (e.g., 2023–2024)
- whether you want brand-only or including generics
- whether you want prescriptions, units, or sales value

I can provide a more precise answer or pull the latest published figures from sources like IQVIA Drug Channels Institute, company annual reports, or market analyses.

If you’d like, I can also outline the main leuprolide formulations and brands you’ll typically see:
- Lupron (brand by AbbVie/Takeda lineage) – commonly the leading brand in many markets
- Eligard (long-acting subcutaneous formulation) – a major competitor in the US
- Viadur (leuprolide implant) – smaller share in many markets
- Generics/injectables – compete on price where available

Tell me what you prefer, and I’ll tailor the data.